ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1365 National Cancer Institute Html en Treatment-Related Nausea and Vomiting (PDQ®)–Health Professional Version Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.
Navari RM0.607101
emetogenic cancer chemotherapy0.63983
Eur J Cancer0.609061
delayed chemotherapy-induced nausea0.625115
prevention0.607994
vomiting0.735606
moderately emetogenic cancer0.588642
Hesketh PJ0.626918
chemotherapy-induced nausea0.995758
patients0.657649
postchemotherapy nausea0.593584
Ann Oncol0.583271
future chemotherapy cycles0.584523
cancer chemotherapy0.674463
postchemotherapy nausea interrelate0.583875
Cancer Treat Rep0.590867
receptor antagonist0.645678
et al.0.731812
multiday chemotherapy regimen.0.581142
study0.614153
3-day chemotherapy regimens0.58215
emetogenic chemotherapy-induced nausea0.655987
high-dose cisplatin chemotherapy0.594488
highly emetogenic chemotherapy0.717945
cisplatin chemotherapy0.641758
delayed cisplatin-induced nausea0.593234
PUBMED Abstract0.729569
moderately emetogenic chemotherapy0.836636
Support Care Cancer0.895503
emetogenic cisplatin-based chemotherapy0.601411
emetogenic multi-day chemotherapy0.600149
Patients Receiving Chemotherapy0.603022
lung cancer chemotherapy0.587479
multiday chemotherapy0.602924
dexamethasone0.645924
Abstract0.798738
cisplatin-induced emesis0.607512
Clin Oncol0.771609
multiday chemotherapy regimen0.588792
chemotherapy regimen0.594004
multiple-day cisplatin chemotherapy0.590292
antiemetic therapy0.590387
emetogenic multiple-day chemotherapy0.598957
antiemetic efficacy0.593069
acute chemotherapy-induced nausea0.663254
breakthrough chemotherapy-induced nausea0.630049
acute nausea0.588031
cisplatin combination chemotherapy0.606904
CLICK HERE
1588 National Cancer Institute Html en Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.
Plexiform fibrohistiocytic tumor0.280012
malignant tumor cells0.307621
cancer treatment0.290865
soft tissue cell0.275637
rare tumor0.289328
Inflammatory myofibroblastic tumor0.282045
childhood soft tissue0.441268
cell tumor0.287204
body0.349975
type0.32132
PDQ cancer information0.285649
children0.277658
clinical trials0.413146
clinical trial0.299958
clear cell sarcoma0.298146
Malignant triton tumor0.279981
blood vessels0.296075
smooth muscle tumor0.277296
lymph nodes0.29136
radiation therapy0.449797
soft tissue sarcoma0.971932
cartilage tumor0.284625
treatment0.443484
synovial sarcoma0.284633
Primitive neuroectodermal tumor0.276261
nerve sheath tumor0.323482
chromosome switches places0.389422
cancer cells0.417787
tumor cells0.415668
tumor suppressor gene0.277153
genetic change0.398935
soft tissue sarcomas0.289965
/extraskeletal Ewing tumor0.27615
fibrous tissue tumor0.342556
tissue sarcoma cells0.300511
primary tumor0.287542
metastatic tumor0.275814
following types0.304501
soft tissue tumors0.283665
PDQ summary0.323186
tumors0.289287
tumor0.552574
Tissue Sarcoma Treatment0.342732
certain genetic change0.378247
cancer0.496155
information0.290056
Adult Soft Tissue0.29745
fast-growing tumor0.287416
CLICK HERE
1642 National Cancer Institute Html en 714-X (PDQ®)–Patient Version 714-X is made by mixing chemicals with camphor, a natural substance that comes from the wood and bark of the camphor tree. Read about the theory behind using 714-X and its current use in cancer patients.
peer-reviewed scientific journals0.537641
treatment0.534968
cancer treatment0.501509
cancer prevention0.385702
Information Service 1-800-4-CANCER0.351897
Complementary Therapies Editorial0.514523
United States0.392202
Cancer Information Specialist0.412867
Drug Administration0.382831
NCI Best Case0.355021
Cancer Information Service0.561203
PDQ cancer information0.744788
Cancer Complementary0.449411
CAM therapies0.422313
treatment clinical trials0.37249
National Cancer Institute0.876336
clinical trials0.717035
alternative medicine0.550954
health care0.367057
scientific journals0.644656
cancer information summary0.608674
alternative cancer therapies0.435258
Federal Trade Commission0.400026
National Institutes0.384082
clinical trial0.420566
National Center0.380596
CAM cancer research0.409541
new treatment0.361031
breast cancer prevention0.380639
PDQ 714-X0.397489
PDQ summaries0.352729
cancer patients0.471011
Cancer Care page0.383195
latest published information0.365664
NCI’s PDQ0.390788
PDQ summary0.383221
Integrative Health0.378723
NCI PDQ cancer0.513504
cancer information database0.431786
alternative therapies0.488998
cancer information summaries0.432385
Therapies Editorial Board0.457631
cancer0.995087
research studies0.395284
714-X0.480793
fight cancer cells0.39917
PDQ Integrative0.349747
CLICK HERE
1662 National Cancer Institute Html en Childhood Craniopharyngioma Treatment (PDQ®)–Patient Version Childhood craniopharyngiomas are benign (not cancer) brain tumors found near the pituitary gland. Learn about the signs, tests to diagnose, and treatment (surgery, radiation therapy, chemotherapy, and immunotherapy) of pediatric craniopharyngioma in this expert-reviewed summary.
cancer treatment0.48468
biologic therapy0.507196
metastatic brain tumors0.486695
ongoing clinical trials0.484802
type0.50142
PDQ cancer information0.574719
clinical trial search0.540589
brain tumors0.522888
clinical trials0.951944
Tumors Treatment Overview0.504097
Pediatric Treatment Editorial0.495313
cancer information summary0.533129
External-beam radiation therapy0.488413
clinical trial0.688299
treatment clinical trial0.507181
NCI PDQ cancer0.492501
radiation therapy0.972274
Treatment Editorial Board0.499227
3-dimensional radiation therapy0.515967
late effects0.510845
currently used treatment0.491406
treatment0.796928
PDQ treatment summary0.532401
pituitary gland0.574023
primary brain tumors0.487104
PDQ Pediatric Treatment0.494857
childhood craniopharyngioma0.61051
Benign brain tumors0.485617
treatment clinical trials0.53534
National Cancer Institute0.529019
tumor cells0.70293
spinal cord0.496884
tumor treatment0.551247
optic nerves0.511248
Childhood Craniopharyngioma Treatment0.498434
new treatment0.547603
external radiation therapy0.527756
brain0.588207
PDQ summary0.519792
effects tumor treatment0.543564
Intracavitary radiation therapy0.548993
radiation treatment0.484529
cancer clinical trials0.558097
tumor0.711831
treatment options0.489122
internal radiation therapy0.557881
cancer0.593059
standard treatment0.499934
spinal cord tumors0.49494
CLICK HERE
1748 National Cancer Institute Html en Formaldehyde and Cancer Risk A fact sheet that discusses formaldehyde and its possible association with cancer. Includes resources for more information.
U.S. Consumer Product0.507182
potential health effects0.45175
nasopharyngeal cancer0.446819
formaldehyde resins0.646729
paper product coatings0.444118
formaldehyde exposure0.974129
cumulative exposure0.471192
case-control studies0.464784
health care professionals0.44942
laboratory studies0.445025
building materials0.458544
highest estimated formaldehyde0.647871
formaldehyde exposure limit0.684002
long-term health effects0.450096
probable human carcinogen0.44463
formaldehyde exposure levels0.675206
industrial workers0.445134
short-term health effects0.476808
Environmental Protection Agency0.476151
workplace exposure0.472844
myeloid leukemia0.515754
high formaldehyde levels0.685556
pressed-wood products0.507453
occupational formaldehyde exposure0.700409
Product Safety Commission0.506904
cohort study0.490021
National Toxicology Program0.502466
household products0.463834
British industry workers0.444394
U.S. Environmental Protection0.477699
occupational exposure0.487391
Occupational Safety0.475151
Emergency Management Agency0.463126
human carcinogen0.45778
National Cancer Institute0.452741
lymphatic systems0.444691
formaldehyde gas0.693298
Health Administration0.456674
NCI cohort0.451429
NCI case-control study0.460446
occupational exposure limits0.480797
Consumer Product Safety0.50691
NCI industrial cohort0.459283
lung cancer deaths0.469841
funeral industry workers0.472946
lung cancer mortality0.44468
formaldehyde content0.617511
prolonged exposure0.474993
CLICK HERE
1756 National Cancer Institute Html en Alcohol and Cancer Risk A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers.
major risk factor0.235988
esophageal cancer0.270931
alcohol content0.304765
alcohol-associated cancer risk0.218724
alcohol dehydrogenase0.277499
Heavy alcohol0.291007
alcohol consumption0.743494
modestly increased risk0.222903
colorectal cancer risk0.261495
alcohol drinkers0.284781
drinking alcohol0.321106
alcohol intake0.325944
ethyl alcohol0.305684
percent alcohol0.349039
moderate alcohol drinking0.333262
Alcohol Abuse0.303318
studies0.234236
cancer risk declines0.219417
alcohol0.928418
pure alcohol0.321046
Moderate alcohol intake0.283695
esophageal squamous cell0.212278
breast cancer risk0.237174
S. Alcohol drinking0.301428
alcohol-related esophageal cancer0.211228
breast cancer0.381145
alcohol drinking0.503002
neck cancers0.250896
pancreatic cancer risk0.215956
neck cancer0.200912
regular alcohol consumption0.359735
et al0.397799
cancer risk0.361737
cancers0.264383
oral cavity0.23106
cancer0.549181
risk0.431925
liver cancer0.219113
enzyme drink alcohol0.313977
CLICK HERE
2016 National Cancer Institute Html es Aspectos generales de la prevención del cáncer (PDQ®)–Versión para pacientes Información general sobre la prevención del cáncer y descripciones de conceptos usados en sumarios específicos sobre la prevención del cáncer.
radiación ionizante causa0.460647
científicos estudian0.489171
Vitamina B120.441748
principales factores0.444309
altos costos0.431231
siguientes tipos0.443767
Vitamina C0.440272
determinadas sustancias0.434346
bacteria helicobacter0.42962
Vitamina B60.441932
Clinical Trials Registry0.438953
vitamina d0.4813
National Cancer Institute0.429703
siguientes riesgos0.428971
alto contenido0.463103
ligera disminución0.41989
vitamina e0.538039
Instituto Nacional0.447408
OmegA-3 TriaL0.424385
antecedentes familiares0.422212
sumario prevención0.489845
Cancer Prevention Trial0.437168
hepatitis b0.427578
Physician Data Query0.503692
células tumorales benignas0.462584
Radiación ultravioleta0.43604
Leucemia mielógena aguda0.449074
Estados Unidos0.563042
prevención revisa0.457445
Physician´s Health Study0.436091
cabo estudios0.425211
PDQ Prevención0.699792
siguientes vitaminas0.436186
siguientes medicamentos0.44035
Gas radón0.426739
PDQ Aspectos0.466808
CLICK HERE
16473 National Cancer Institute Html en Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
platinum-based chemotherapy0.436007
immune checkpoint inhibitor0.707571
pembrolizumab block0.240544
checkpoint inhibitor nivolumab0.489462
standard therapy group0.856853
HNSCC tumor growth0.401684
squamous cells0.272124
Cancer Therapy Evaluation0.372634
overall survival0.94063
broader group0.255871
poor prognoses0.250488
median progression-free survival0.452131
Pittsburgh Medical Center0.399432
Maura L. Gillison0.401307
Bristol-Myers Squibb0.274378
median overall survival0.493854
patients0.514717
metastatic HNSCC0.274208
HNSCC0.412159
effective second-line therapy0.394916
Shakun Malik0.250672
Drug Administration0.252661
cancer cells0.262643
treatment-related adverse events0.35048
Human papillomavirus0.256631
better treatment0.263098
unacceptable side effects0.245803
median follow-up0.28334
PD-L1—a molecule0.240638
nivolumab group0.622355
tumor cells0.248287
new trial0.243059
standard chemotherapy0.417786
Ohio State University0.396086
median length0.283635
immune cells0.271394
salivary glands0.258435
nasal passages0.247938
Robert L. Ferris0.397098
Cancer Institute0.278018
neck cancer0.259993
tumor response0.240293
common adverse events0.34039
New England Journal0.393835
oral cavity0.246829
checkpoint molecule PD-10.389662
Earlier studies0.247274
phase III trial0.261728
CLICK HERE
16718 National Cancer Institute Html es Estudios clínicos de cáncer en el Centro Clínico de los Institutos Nacionales de la Salud Información acerca de los estudios clínicos de cáncer en el Centro Clínico de NIH en Bethesda, Maryland.
Centro Clínico0.997868
investigación clínica0.340866
Estados Unidos0.385246
Institutos Nacionales0.316065
CLICK HERE
16850 National Cancer Institute Html es Sulfato de hidracina (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.
cancer treatment0.309808
Cancer Res Clin0.314959
patients with weight0.313024
Bhide SV0.308798
Lung tumor induction0.305602
Leukemia Group B0.306125
Leukemia Group0.310364
Toth B0.324797
intramuscular carcinoma0.305811
Cancer Res0.346197
clinical study0.310429
clinical trial0.304403
Filov VA0.304814
Res Clin Oncol0.306832
Estados Unidos0.307293
Natl Cancer Inst0.349481
Kosty MP0.307691
repuesta tumoral objetiva0.307141
investigational new drug0.305732
Danova LA0.311765
non-small cell lung0.304038
patients with0.351997
investigación clínica0.304586
Gershanovich ML0.316882
evaluable patients0.305223
studies with0.304111
Control Clin Trials0.304096
new drugs0.310502
Regelson W0.307129
National Toxicology Program0.310712
diagnosed non-small-cell lung0.308493
Grosvenor M0.308061
Nutr Cancer0.31929
clinical study antitumor0.304647
Gold J0.349764
treatment with0.310953
Herndon JE0.307454
Cancer Treatment Group0.306186
Treat Rep0.305235
nutritional status0.304262
Invest New Drugs0.305807
Clin Oncol0.367278
Chlebowski RT0.319227
hydrazine sulfate0.975261
Bulcavage L0.308142
Mutat Res0.30448
treated with0.304341
lung tumours0.306046
treatment with sehydrin0.310193
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.